EUVIMEDEUVIMED entdecken
EditorialKommentar

The Search for a Reliable Biomarker in MEN1 Duodenopancreatic Neuroendocrine Tumors

Daniel Bulzico iD

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgad521 ↗

Kurz gefasst

Editorial in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Daniel Bulzico. Beteiligte Einrichtung: Endocrine Oncology Unit and Nuclear Medicine Section, Brazilian National Cancer Institute, Rio de Janeiro, CEP 20230-130, Brazil. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prognosis of multiple endocrine neoplasia type 1 (MEN1) patients has improved substantially over past decades. The disease-related mortality rate has been decreasing mainly because of the dramatic reduction of peptic ulcer disease complications since the development of proton pump inhibitors but also due to the improvement in operative technics. Currently, most MEN1 patients will die from thymic and duodenopancreatic neuroendocrine tumors (dpNET), the leading cause of MEN1-related death among this population (1). Differently from MEN2 medullary thyroid carcinoma, which can be managed prophylactically with a thyroidectomy guided by a well-known genotype-phenotype correlation (2), an early diagnosis is still the best we can accomplish in terms of MEN1 dpNET. Once diagnosed, prognostic factors should be able to dictate therapeutic and surveillance procedures, especially in those cases identified as prone to develop distant metastasis, taking into account the absence of a well-defined genotype-phenotype clinical correlation in MEN1. In the Journal of Clinical Endocrinology and Metabolism, Katayama and colleagues reported the novel circulating biomarkers associated with disease progression (3). The results presented are derived from recent previous work where the same group described the potential role of blood-based polyamines in monitoring an aggressive disease presentation in MEN1 patients (4). This time, using a proteomics algorithm, the authors not only identified a unique plasma protein signature in dpNET metastatic cases when compared to 2 control groups—1 with nonmetastatic dpNET and a second one composed of MEN1 patients with no dpNET—but also determined a pattern of protein secretion in terms of dpNET development and progression in a MEN1 murine model. Most intriguing, during a cross-species intersection analysis, they found 19 proteins that were concordantly related to the presence of distant metastasis in humans and also to disease progression in the animal model (3).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsMultiple Endocrine Neoplasia Type 1Pancreatic NeoplasmsHumansProteomicsBiomarkers

Stichwörter der Autor:innen

MEN1biomarkerneuroendocrine tumorprognosis

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Endocrine Oncology Unit and Nuclear Medicine Section, Brazilian National Cancer Institute, Rio de Janeiro, CEP 20230-130, Brazil.

ORCID-Profile: Daniel Bulzico

Zitieren

APA

Bulzico, D. (2024). The Search for a Reliable Biomarker in MEN1 Duodenopancreatic Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad521

Vancouver

Bulzico D. The Search for a Reliable Biomarker in MEN1 Duodenopancreatic Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad521

BibTeX
@article{Bulzico2024,
  author = {Bulzico, Daniel},
  title = {The Search for a Reliable Biomarker in MEN1 Duodenopancreatic Neuroendocrine Tumors},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgad521}
}
Kostenlos starten →